As a pharmaceuticals manufacturer, Duopharma Biotech seeks to minimise as far as possible any negative footprint we have while putting in place systems and processes to create positive outcomes. Our Climate Performance-related initiatives cover carbon emissions and energy usage reduction, improving water management efficiency as well as reduction in waste generation.
Human activities have released greenhouse gases (GHG), driving global warming and consequential climate change impacts such as severe droughts, rising sea levels, increased flooding, and more frequent intense storms. At Duopharma Biotech, we’re committed to mitigating these effects by continuously improving our GHG monitoring and reporting mechanisms, with a focus on carbon emissions, as we move toward a carbon-neutral path. Our goal is to annually reduce 10% of our Scope 2 carbon emissions and ultimately achieve Carbon Neutrality by 2030 and Net Zero Carbon Emissions by 2050. In 2022, we began our Scope 3 accounting journey by prioritizing significant Scope 3 emission sources and established a GHG Scope 3 Roadmap – six categories of GHG Scope 3 were identified as relevant to report.
Our Climate Roadmap details a spectrum of strategies covering short, medium, and long-term approaches to reduce carbon emissions and improve energy efficiency. Simultaneously, we are in the process of establishing our Net Zero Transition Plan (“NZTP”), which is a strategic framework that outlines key enablers and initiatives that will support Duopharma Biotech in its transition into Net Zero carbon emissions organization by 2050 in line with the global objective of limiting the rise in global temperatures to a maximum of 1.5°C above pre-industrial levels. The implementation of these initiatives will also facilitate the attainment of Carbon Neutral by 2030 target.
Water is a pressing need in many areas of the world. Water scarcity may impose high risk to operations as water is needed to grow and process food, create energy, and serve industry for a continually growing population. At Duopharma Biotech, we believe the importance of comprehensive water management, which is managed through monitoring of water consumption, implementing water efficiency initiatives and proper management of effluents and wastewater to protect water resources.
At Duopharma Biotech, we believe the importance of comprehensive water management. We established water management plan for all three main manufacturing sites in Klang, Bangi and Glenmarie. The water management plan includes guidelines and procedures to monitor water consumption and recyling, proper management of effluents and wastewater (monitoring of effluent characteristics), and the implementation of water efficiency initiatives. The outcome of the monitoring (water usage and quality) are presented to the Management Committee on monthly basis, whereas effluent characteristics are presented to Environmental Performance Monitoring Committee (EPMC) every quarter.
Reduce the amount of water required for business, increase return water back to source, recycling and efficiency.
Increasing water visibility to identify water flow and consumption.
Implement targets and solutions to increase water treatment and employ advanced technologies/vendors to reach targets.
Phase out pharmaceuticals from effluent water discharge.
Protect local water resources to improve access to clean water for drinking and sanitation.
When waste is disposed of or recycled in a safe, ethical, and responsible manner, it helps reduce the negative impacts to the environment. Ensuring that waste and material management procedures are carried out responsibly and with regularity helps to avoid unnecessary waste generation. At Duopharma Biotech, we strive to ensure efficient use of materials, adopt best practices in waste disposal, strengthening our recycling efforts and ensuring compliance to relevant environmental laws and regulations throughout our operations.
We recognize the increasing urgency of managing climate-related risks throughout our activities and operations, and we are actively addressing this concern. ‘Climate Risk’ has been identified as one of our top 10 material sustainability matters, reflecting its significance in our strategy.
Current efforts primarily focus on mitigation actions, including energy efficiency initiatives, the installation of solar panels, and the utilization of waste reduction thermal systems to reduce scheduled waste disposal to landfills. These measures are essential to reduce our environmental footprint. In parallel, we have initiated the identification of climate adaptation actions to enhance climate resilience. For instance, we are ensuring that all new facilities are constructed above sea level, fortifying our infrastructure against sea-level rise. Detailed adaptation strategies will be elaborated upon in the near future.
Moreover, our comprehensive climate risk management measures encompass the assessment of climate-related risks and impacts for all new projects before approval and commencement, their subsequent inclusion in Enterprise Risk Management (ERM) for continuous monitoring and mitigation, and oversight by our Board of Directors, who incorporate ESG and climate-related risks into their decision-making processes as a vital assessment requirement.